• 제목/요약/키워드: antithrombotic therapy

검색결과 17건 처리시간 0.023초

치과에서 시행되고 있는 시술 전 항혈전제 관련 처치에 대한 실태 파악 (Identify the status of pretreatment on antithrombotic agents in practice at the dentist's office)

  • 한아름
    • 한국노년학
    • /
    • 제40권2호
    • /
    • pp.227-237
    • /
    • 2020
  • 최근 노인 인구에서 심뇌혈관 질환 환자들이 증가하면서 항혈전제 치료를 받는 환자들이 늘고 있다. 치과시술 전 항혈전제 중단에 대한 가이드라인이 있지만 실제 임상에서는 가이드라인과 다르게 적용하고 있어, 관리 실태 및 출혈에 대한 인식정도를 파악하기 위해 본 연구를 진행하였다. 연구방법은 치과의사들이 가입된 최대규모의 싸이트를 통해 설문지를 수집하였으며 이 중 설문연구 가치가 있는 자료 총 1000장의 설문지를 확보하였다. 설문조사내용은 일반적인 사항을 묻는 문항과 항혈전제 사용 병력 기록, 항혈전제로 인한 합병증 경험여부, 사용중단 여부, 사용중단 이유, 사용 중단 기간 등을 묻는 인식도 조사항목으로 이루어졌다. 연구결과는 환자의 항혈전제 사용 여부를 기록하는 비율은 92%로 높았고, 항혈전제 사용시 나타나는 지연출혈을 경험한 빈도는 55.1%, 발치 전 항혈전제 복용을 중단시키는 빈도는 87.8%, 중단이유가 지연출혈이라고 응답한 빈도는 98.3%, 중단 기간은 3-5일이 64%로 제일 높았다. 다음과 같은 점을 논의하였다. 임상현장에서는 지연출혈 정도나 빈도가 더 높거나 한국인 치과의사들은 환자의 정서적 문제, 환자 의사와의 관계, 추가적으로 발생되는 사회경제적인 문제를 고려해서 가이드라인보다 더 엄격하게 지연출혈에 대해 대처하고 있다고 해석된다.

중등도 이상의 위험 수술을 받은 환자에서 수술 전후 항혈전제 약물 사용 평가 (Evaluation of Perioperative Antithrombotic Management in Patients Undergoing Moderate to High Risk Surgery)

  • 이현아;조윤희;조윤숙;한현주;이주연;정근화;이상건
    • 한국임상약학회지
    • /
    • 제27권1호
    • /
    • pp.15-21
    • /
    • 2017
  • Objective: The perioperative management of antithrombotic therapy is often challenging and it requires a fine balance between the risk of hemorrhage and thrombosis. We aimed to evaluate the antithrombotic management for moderate to high risk patients in real world setting. Methods: Among the patients who were consulted to the neurologist for the evaluation of perioperative risk from 2010 to 2012, patients undergoing moderate to high risk surgery and taking antithrombotics within 30 days were identified. We analyzed the timing of discontinuation and reinitiation of antithrombotic drugs before or after surgery as well as the status of bridging therapy. In addition, the conformity with the guideline suggested by American College of Chest Physicians was assessed. The rate of thromboembolic event and major hemorrhage were also investigated. Results: A total of 329 patients were included. The concordance rate of warfarin stop and restart time with guideline was 23.4% and 10.3%, respectively. Continuing aspirin in patients undergoing coronary artery bypass surgery or non-cardiac surgery in patients with high risk for cardiovascular events were 59.2% and 2.6%, respectively. Bridging therapy was adopted in 92.9% and 81.2% in patients who had received anticoagulant before surgery and who were at high and low risk thromboembolism, respectively. In entire cohorts, 30-day incidence of major bleeding and thromboembolic event were 31.9% and 3.0%. Co-morbid renal disease were shown as independent predictor for major bleeding (adjusted OR 2.65. 95% CI 1.33-5.28). Conclusion: The concordance rate with guideline regarding perioperative antithrombotic use was low and bridging therapy was prevalent in patients undergoing moderate to high risk surgery.

현호색산의 항혈전작용에 대한 연구 (The Experimental Studies on Antithrombotic Effects of Hyunhosaiksan)

  • 임민철;김동희
    • 동의생리병리학회지
    • /
    • 제17권4호
    • /
    • pp.930-938
    • /
    • 2003
  • The purpose of the present study was to investigate the effects of Hyunhosaiksan (HHS) on antithrombotic actions which include blood activation, thrombus removal, warming of circulating blood, and the control of pain on abdomen and lower and upper burning spaces. HHS significantly inhibited platelet aggregation induced by ADP and epinephrine in a HHS dose-dependent manner when analyzed by the Sigmoid Emax model in WinNonlin. EC50 values of HHS were 1.71 ㎍/ml and 0.004 ㎍/ml for ADP and epinephrine respectively. In the vivo study, HHS inhibited pulmonary embolism induced by collagen and epinephrine, which was however statistically insignificant. HHS increased number of platelets, APTT and volume of fibrinogen significantly as compared with the control group in dextran-induced thrombus model. Furthermore, HHS stimulated levels of blood flow in vivo though its effect was not observed in vitro. These results suggest that Hyunhosaiksan (HHS) can be used for treating numerous diseases related with blood aggregation and circulation problems. Further systematic investigations on the synergic effects among drugs used in the oriental medicine as well as in the western medicine in relation to thrombosis therapy would provide an important insight into the potential therapeutic applications.

허혈성 뇌졸중에서의 항혈전 치료 (Antithrombotic Therapy for Ischemic Stroke)

  • 하정상;이준
    • Journal of Yeungnam Medical Science
    • /
    • 제20권1호
    • /
    • pp.1-12
    • /
    • 2003
  • Ischemic stroke is among the principal causes of death and disability in the elderly. Although control of blood pressure, decreased cigarette smoking, and modified dietary habits are among important reasons for stroke decline, the use of antithrombotic therapy, rigorously prescribed. Several antiplatelet agents are approved to reduce the risk of recurrent stroke. Aspirin is the best-studied and most widely used antiplatelet agent for stroke prevention; it provides approximately 15% to 25% relatively risk reduction for secondary prevention of stroke or the major vascular death. Combining 2 antiplatelet agents with different mechanism of action was demonstrated to provide a substantial increase in efficacy in several studies. Anticoagulation should be considered first with potential cardiac sources of embolism. Heparin reduces development of erythrocyte-fibrin thrombi that form in regions of vascular stasis especially within the heart, in severely stenosed arteries sometimes engrafted on white thrombi, in acute arterial occlusion. Heparin should not be indiscriminately given to all acute brain ischemia patients, but may contribute to treatment of large artery occlusion and severe stenosis, cardiogenic embolism with a high acute recurrence risk, and dural sinus and cerebral venous thromobosis.

  • PDF

하고초 추출물의 항혈전 효능 및 혈소판 응집 억제작용 (Antithrombotic and Antiplatelet Activity of Extract from Prunella vulgaris)

  • 양원경;성윤영;김호경
    • 생명과학회지
    • /
    • 제21권10호
    • /
    • pp.1422-1427
    • /
    • 2011
  • 한방생약제의 항혈전 및 혈소판 응집 억제 효능을 탐색하기 위하여 하고초의 물 추출물로 혈전 용해능 활성과 혈액 응고시간 지연효과 즉 PT (prothrombin time), APTT (activated partial thromboplastin time)와 혈소판 응집억제 활성 등에 대해 항혈전 효능을 평가하였다. 혈전용해도를 측정하는 fibrin plate가 용해되어 형성된 투명환의 넓이를 측정하는 실험을 진행한 결과 혈전용해도가 농도의존적으로 효능을 나타내었다. 혈액 응고 cascade에 미치는 영향을 알아보기 위해 혈액 응고 시간 지연 및 단축 효과를 확인하고자 APTT와 PT에 미치는 영향을 조사한 결과 PT의 경우 10 mg/ml, 5 mg/ml의 경우에는 대조군보다 우수한 지연효과를 보였다. APTT의 경우에는 10 mg/ml, 5 mg/ml는 대조군과 비교하여 매우 탁월한 지연효과를 보이고, 2.5 mg/ml, 1.25 mg/ml에서도 높은 지연효과를 나타냈다. 혈소판의 응집에 따라 형성되는 두 전극 사이에 형성된 전기적 저항의 변화로 나타나는 실험을 시행한 결과 하고초의 ADP와 collagen에서 뛰어난 응집억제 활성을 보였다. 따라서 위의 항혈전 효능평가 실험결과를 볼 때 하고초를 향후에 혈전 질환의 치료제 개발에 효과적으로 이용될 수 있을 것으로 사료된다.

8과 1/2 증후군 2례 (Eight and a Half Syndrome: A Clinical Study of 2 Cases)

  • 박지민;김종한;유제혁;윤가영;남동우;이상훈;김종인
    • Journal of Acupuncture Research
    • /
    • 제29권3호
    • /
    • pp.139-148
    • /
    • 2012
  • Objectives : The purpose of this case is to report the improvement of two patients diagnosed with eight and a half syndrome after combination therapy of oriental and western medicine. Methods : We treated the patients with combination therapy of oriental and western medicine such as acupuncture, moxibustion, herbal medication, antithrombotic agents and steroid therapy. Changes of peripheral facial paralysis were evaluated using House-Brackmann facial grading system and the degree of dizziness, tenderness and pain of upper abdomen were assessed using numerous rating scale. Changes in motor grade of upper and lower extremities were evaluated using medical research council scale. Results : We have recently experienced two cases of eight and a half syndrome - a syndrome characterized by the coexistence of one and a half syndrome, a rare ophthalmoparetic syndrome characterized by a conjugate horizontal gaze palsy in one direction and an internuclear ophthalmoplegia in the other, and cranial nerve VII palsy. The one and a half syndrome was caused by acute cerebral infarction. Two patients in this report were improved through combination therapy of oriental and western medicine. Conclusions : We report the clinical course and treatment methods of eight and a half syndrome.

Alternative Mechanism of Aspirin in Anti-Thrombotic Therapy: Inhibition of Thrombin Activatable Fibrinolysis Inhibitor

  • An, Seong-Soo A.;Greenfield, Robert S.
    • Bulletin of the Korean Chemical Society
    • /
    • 제33권9호
    • /
    • pp.3048-3054
    • /
    • 2012
  • The use of aspirin is widely recommended for the prevention of heart attacks owing to its ability to inhibit platelet activation by irreversibly blocking cyclooxygenase 1. However, aspirin also affects the fibrinolytic and hemostatic pathways by mechanisms that are not well understood, causing severe hemorrhagic complications. Here, we investigated the ability of aspirin and aspirin metabolites to inhibit thrombin-activatable fibrinolysis inhibitor (TAFI), the major inhibitor of plasma fibrinolysis. TAFI is activated via proteolytic cleavage by the thrombin-thrombomodulin complex to TAFIa, a carboxypeptidase B-like enzyme. TAFIa modulates fibrinolysis by removing the C-terminal arginine and lysine residues from partially degraded fibrin, which in turn inhibits the binding of plasminogen to fibrin clots. Aspirin and its major metabolites, salicylic acid, gentisic acid, and salicyluric acid, inhibit TAFIa carboxypeptidase activity. Salicyluric acid effectively blocks activation of TAFI by thrombin-thrombomodulin; however, salicylates do not inhibit carboxypeptidase N or pancreatic carboxypeptidase B. Aspirin and other salicylates accelerated the dissolution of fibrin clots and reduced thrombus formation in an in vitro model of fibrinolysis. Inhibition of TAFI represents a novel hemostatic mechanism that contributes to aspirin's therapy-associated antithrombotic activity and hemorrhagic complications.

심장판막치환환자와 항응혈치료 (Cardiac Valve Replacement and Anticoagulation)

  • 김종환
    • Journal of Chest Surgery
    • /
    • 제11권3호
    • /
    • pp.303-315
    • /
    • 1978
  • During the full 10-year period from June 1968 through June 1978, 112 consecutive patients underwent isolated or double valve replacement. A total of 130 valves were used in aortic, mitral or tricuspid positions: 63 prosthetic valves in 56 and 67 glutaraldehyde-preserved porcine aortic valves in 56 patients. There were 31 early and 9 late deaths with a cumulative mortality rate of 35.7 percent. Eighty-five patients survived longer than 10 days postoperatively were studied for the occurrence of thromboembolism and complications related to anticoagulant therapy. At the end of follow-up period, 68 patients were on Coumadin; 74 were on Persantin with or without Coumadin; 11 were off any antithrombotic drugs with 6 of them being off electively after 6 months of tissue valve replacement. Thromboembolism occurred in 7 [8.2%] of 85 patients or 10.9%/patient-year. Embolic rates were as follows: one of 18 patients anticoagulated [5.6%] or 6.1%/patient-year and 4 of 16 patients not anticoagulated [25.0%] or 17.8%/patient-year for the prosthetic valve replacement; and one of 40 patients anticoagulated [2.5%] or 7.9%/patient-year and one of 11 patients not anticoagulated [9.1%] or 7.9%/patient-year for tissue valve replacement. Three complications of major bleeding were experienced by 3 patients during the follow-up period, being related to Coumadin therapy. The importance of proper anticoagulation were stressed for the successful management of patients after cardiac valve replacement, both prosthetic and tissue valves.

  • PDF

Prevalence of Aspirin Resistance and Clinical Characteristics in Patients with Cerebral Infarction

  • Choi, Jong-Tae;Shin, Kyung-A;Kim, Young-Kwon
    • 대한의생명과학회지
    • /
    • 제19권3호
    • /
    • pp.233-238
    • /
    • 2013
  • Aspirin is still the mainstay of antiplatelet therapy in the cardiovascular and cerebrovascular disease. However, some patients are not responsive to the antithrombotic action of aspirin. The aim of this study was to assess the prevalence and clinical characteristics of aspirin resistance in patients with cerebral infarction. We tested platelet function in 557 patients who had been treated with aspirin in J general hospital. Platelet function was tested using the multiple electrode platelet aggregometry (MEA). Platelet reactivity was expressed as area under the aggregation curve (AUC, U) and >30 AUC was defined as aspirin resistance. Aspirin resistance was detected in 16.2% patients. There was not any significant differences in age, gender between aspirin resistance and aspirin sensitive patients. WBC was significantly higher in patients with aspirin resistance (P < .05). HDL-cholesterol was significantly higher in patients with aspirin sensitive (P < .05). Aspirin resistance was positive correlation with platelet count (r =.314, P =.003). The prevalence of aspirin resistance in cerebral infarction was 16.2%, and platelet count were related with aspirin resistance.